Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 18 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $154,090, and 14 were calls, valued at $1,229,175.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $840.0 for Eli Lilly and Co, spanning the last three months.
Volume & Open Interest Development
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly and Co's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly and Co's whale activity within a strike price range from $240.0 to $840.0 in the last 30 days.
Eli Lilly and Co Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BULLISH | 06/21/24 | $538.0 | $533.0 | $538.0 | $240.00 | $538.0K | 11 | 10 |
| LLY | CALL | TRADE | BEARISH | 08/16/24 | $51.6 | $49.65 | $49.65 | $780.00 | $248.2K | 332 | 4 |
| LLY | CALL | TRADE | BEARISH | 08/16/24 | $25.75 | $25.25 | $25.25 | $840.00 | $75.7K | 113 | 0 |
| LLY | PUT | TRADE | NEUTRAL | 05/10/24 | $5.85 | $5.4 | $5.66 | $775.00 | $56.6K | 101 | 14 |
| LLY | CALL | SWEEP | BULLISH | 05/31/24 | $22.5 | $21.35 | $22.5 | $770.00 | $54.0K | 287 | 0 |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly and Co, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of Eli Lilly and Co
- With a trading volume of 578,252, the price of LLY is down by -0.36%, reaching $775.0.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 90 days from now.
Professional Analyst Ratings for Eli Lilly and Co
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $826.0.
- Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $815.
- An analyst from Truist Securities persists with their Buy rating on Eli Lilly and Co, maintaining a target price of $892.
- An analyst from Goldman Sachs has decided to maintain their Neutral rating on Eli Lilly and Co, which currently sits at a price target of $723.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $815.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $885.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly and Co options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
